Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FGFR2 |
Variant | L618M |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | FGFR2 L618M (corresponds to L617M in the canonical isoform) lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). L618M results in increased Fgfr2 kinase activity, enhanced cell proliferation in the presence of ligand in culture (PMID: 23908597), and elevated kinase activity compared to wild-type Fgfr2 protein in substrate phosphorylation assays (PMID: 28166054). |
Associated Drug Resistance | |
Category Variants Paths |
FGFR2 mutant FGFR2 act mut FGFR2 L618M |
Transcript | NM_022970.4 |
gDNA | chr10:g.121496546A>T |
cDNA | c.1852T>A |
Protein | p.L618M |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_022970.4 | chr10:g.121496546A>T | c.1852T>A | p.L618M | RefSeq | GRCh38/hg38 |
XM_017015925 | chr10:g.121485444G>T | c.1852C>A | p.L618M | RefSeq | GRCh38/hg38 |
NM_022970 | chr10:g.121496546A>T | c.1852T>A | p.L618M | RefSeq | GRCh38/hg38 |
NM_001144913 | chr10:g.121496546A>T | c.1852T>A | p.L618M | RefSeq | GRCh38/hg38 |
XM_017015925.2 | chr10:g.121485444G>T | c.1852C>A | p.L618M | RefSeq | GRCh38/hg38 |
NM_001144913.1 | chr10:g.121496546A>T | c.1852T>A | p.L618M | RefSeq | GRCh38/hg38 |
NM_022970.3 | chr10:g.121496546A>T | c.1852T>A | p.L618M | RefSeq | GRCh38/hg38 |
XM_017015925.3 | chr10:g.121485444G>T | c.1852C>A | p.L618M | RefSeq | GRCh38/hg38 |
NM_001144913.1 | chr10:g.121496546A>T | c.1852T>A | p.L618M | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 L618M | Advanced Solid Tumor | decreased response | Dovitinib | Preclinical | Actionable | In a preclinical study, transformed cells expressing FGFR2 L618M demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597). | 23908597 |
FGFR2 L618M | Advanced Solid Tumor | sensitive | Ponatinib | Preclinical | Actionable | In a preclinical study, transformed cells expressing FGFR2 L618M were sensitive to treatment with Iclusig (ponatinib) (PMID: 23908597). | 23908597 |
FGFR2 L618M | Advanced Solid Tumor | decreased response | PD173074 | Preclinical | Actionable | In a preclinical study, transformed cells expressing FGFR2 L618M demonstrated a decreased response to treatment with PD173074 (PMID: 23908597). | 23908597 |